A new look at United States drug development and approval times

American Journal of Therapeutics

Volumn 3, Issue 9, 1996, Pages 647-657

  DiMasi, Joseph A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

approved time; clinical development time; Food and Drug Administration

Indexed keywords

NEW DRUG;

CLINICAL TRIAL; DRUG APPROVAL; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; REVIEW; TIME;

EID: 0029967936     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199609000-00008     Document Type: Review

References (14)

1. Kaitin KI, Manocchia M, Seibring MA, Lasagna L: The new drug approvals of 1990, 1991, and 1992: trends in drug development. J Clin Pharmacol 1994;34:120-127.
2. DiMasi JA, Seibring MA, Lasagna L: New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther 1994;55:609-622.
3. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L: Cost of innovation in the pharmaceutical industry. J Health Econ 1991;10:107-142.
4. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L: Research and development costs for new drugs by therapeutic category. PharmacoEconomics 1995;7:152-169.
5. DiMasi JA, Grabowski HG, Vernon J: R&D costs, innovative output, and firm size in the pharmaceutical industry. Int J Econ Business 1995;2:201-219.
6. FDA drug approval: review time has decreased in recent years. (GAO/PEMD-96-1) Washington, DC: United States General Accounting Office, Oct 1995.
7. Third annual performance report - Prescription Drug User Fee Act of 1992: fiscal year 1995 report to Congress. Food and Drug Administration, Rockville, MD, 1995.
8. Hausman JA, Wise DA: Social experimentation, truncated distributions, and efficient estimation. Econometrica 1977;45:919-938.
9. Maddala GS: Limited dependent and qualitative variables in econometrics (Econometric Society Monograph Series No. 3). Cambridge University Press, Cambridge, 1983, pp 165-170.
10. DiMasi JA: Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995;58: 1-14.
11. Kmenta J: Elements of econometrics, 2nd ed. Macmillan Publishing Company, New York, 1986, pp. 419-420.
12. Kessler DA: Statement before the Committee on Labor and Human Resources, US Senate, February 21, 1996. Department of Health and Human Services, Rockville, MD, 1996.
13. Shulman SR, Hewitt P, Manocchia M: Studies and inquiries into the FDA regulatory process: an historical review. Drug Inf J 1995;29:385-413.
14. Peck CC: Modernizing effectiveness and safety testing in drug development. Statement before the Committee on Labor and Human Resources, US Senate, February 21, 1996.